Recombinant Human GIGYF2 Protein: Handling & Usage Protocol

Recombinant Human GIGYF2 Protein is a eukaryotically expressed research reagent designed for scientists investigating mRNA translational repression, GRB10-mediated signaling, and the molecular mechanisms underlying neurodegenerative disease.

Product Name

Recombinant Human GIGYF2 Protein

SKU

rp372303

Gene / Protein

GIGYF2 (GRB10-Interacting GYF Protein 2, also known as PERQ2)

Expression System

Recombinant (eukaryotic system recommended for proper folding; confirm exact host in datasheet)

Primary Research Areas

mRNA translational regulation, miRNA-mediated silencing, neurodegenerative disease (Parkinson's disease association reported), insulin signaling

Recommended Storage

-80 °C for long-term storage; avoid repeated freeze-thaw cycles (confirm exact buffer and stabilizer on CoA)

Reference Source

absea #PP-6351 (internal cross-reference)

Background and Biological Significance of GIGYF2

GIGYF2 (GRB10-Interacting GYF Protein 2) is a large scaffold protein encoded by the GIGYF2 gene in humans. It belongs to the GIGYF protein family, characterized by the presence of a GYF (glycine-tyrosine-phenylalanine) domain that mediates proline-rich sequence interactions. GIGYF2 functions as a key regulator of mRNA translation, acting in concert with the 4EHP (eIF4E2) cap-binding protein to repress cap-dependent translation of target transcripts. It also participates in miRNA-mediated gene silencing pathways by bridging Argonaute complexes to translational repressors.

Beyond its role in translational control, GIGYF2 has been linked to GRB10-mediated insulin and IGF-1 receptor signaling, positioning it at the intersection of growth factor signaling and gene expression regulation. Genetic association studies have reported links between GIGYF2 variants and susceptibility to Parkinson's disease, making GIGYF2 a protein of significant interest in neurodegeneration research. Recombinant Human GIGYF2 Protein enables researchers to dissect these molecular interactions in vitro using biochemical and cell-based approaches.

Reagents, Equipment, and Pre-Experimental Preparation

Required reagents and consumables:

• Recombinant Human GIGYF2 Protein (rp372303, Aladdin Scientific)
• Sterile, nuclease-free deionized water or reconstitution buffer (as specified on the Certificate of Analysis)
• PBS (pH 7.4) or HEPES-based binding buffer suitable for the intended assay
• Protein LoBind microcentrifuge tubes (to minimize adsorption)
• BSA (1 mg/mL) or carrier protein for dilution stability, if recommended on CoA
• SDS-PAGE and Western blot reagents for quality verification
• Protease inhibitor cocktail (if downstream proteomics applications are intended)

Equipment:

• Calibrated micropipettes and sterile barrier tips
• Microcentrifuge (capable of ≥10,000 × g)
• –80 °C freezer and –20 °C freezer
• Ice bucket or cooling block for handling on ice
• UV-Vis spectrophotometer or BCA/Bradford assay kit for protein quantification

Important pre-experimental notes: Always retrieve the specific Certificate of Analysis (CoA) for your lot number, as reconstitution volume, buffer composition, and confirmed purity may vary between lots. Confirm expression host and tag information from the CoA before designing pull-down or co-immunoprecipitation experiments.

Step-by-Step Protocol: Reconstitution, Storage, and Quality Check

Step 1 – Thawing and initial centrifugation: Remove the vial from –80 °C storage and allow it to thaw gently on ice (10–15 minutes). Once thawed, briefly centrifuge the vial (1,000–2,000 × g, 30 seconds) to consolidate any material on the cap or walls before opening.

Step 2 – Reconstitution: If supplied as lyophilized powder, reconstitute by adding the volume of sterile reconstitution buffer specified on the CoA directly to the side of the vial (not directly onto the lyophilized cake) to minimize foaming. Gently swirl or rotate the vial; do NOT vortex. Allow dissolution for 5–10 minutes at room temperature or on ice. If supplied as a liquid, proceed directly to Step 3.

Step 3 – Protein quantification: Determine the actual protein concentration using a BCA or Bradford assay with BSA as the standard, or by absorbance at A280 using the extinction coefficient provided on the CoA. Compare with the stated concentration to assess recovery.

Step 4 – Quality verification by SDS-PAGE: Run a small aliquot (1–2 µg) under reducing and non-reducing conditions on SDS-PAGE (typically 4–12% Bis-Tris gel). Stain with Coomassie or silver stain. Confirm band size is consistent with the expected molecular weight of GIGYF2 (full-length human GIGYF2 is approximately 150–160 kDa; confirm exact predicted MW from CoA as it depends on construct and tags). Purity should be ≥80% or as stated on CoA.

Step 5 – Aliquoting and storage: Divide the reconstituted protein into single-use aliquots appropriate for your experimental needs to avoid repeated freeze-thaw cycles. Store working aliquots at –80 °C. For short-term use within 1–2 weeks, storage at 4 °C may be acceptable if a carrier protein (e.g., 0.1% BSA) is included; verify this against CoA recommendations. Add a glycerol to a final concentration of 5–10% if long-term –20 °C storage is required per CoA guidance.

Step 6 – Functional validation (optional but recommended): Before use in critical experiments, perform a binding or pull-down assay with a known interacting partner (e.g., 4EHP/eIF4E2 or a GYF-domain ligand) to confirm biological activity. This step is strongly recommended when using a new lot.

Experimental Applications and Assay Guidance

Recombinant Human GIGYF2 Protein (rp372303) is suitable for the following research applications. Optimal conditions should be determined empirically for each experimental system.

1. In vitro protein–protein interaction (PPI) assays: GIGYF2 can be used as bait or prey in pull-down assays to identify or validate binding partners. The GYF domain engages proline-rich motifs; use GST- or His-tagged constructs of candidate partners for pull-down confirmation. Recommended binding buffer: 50 mM HEPES pH 7.4, 150 mM NaCl, 0.05% Tween-20, 1 mM DTT.

2. Co-immunoprecipitation (Co-IP) validation: Spike recombinant GIGYF2 into cell lysates or combine with purified recombinant interacting proteins to validate antibody-based Co-IP workflows. Confirm tag compatibility with immunoprecipitation resin.

3. mRNA cap-dependent translation repression assays: In cell-free translation systems (e.g., rabbit reticulocyte lysate or wheat germ extract), addition of exogenous recombinant GIGYF2 can be used to investigate its role in repressing cap-dependent translation in conjunction with 4EHP.

4. ELISA and lateral flow assay development: Use as a coating or capture antigen standard for developing or validating GIGYF2-specific immunoassays and antibody screening.

5. Structural and biophysical studies: Suitable as a component for SPR (surface plasmon resonance), ITC (isothermal titration calorimetry), or MST (microscale thermophoresis) to characterize binding kinetics with small molecules, peptides, or partner proteins.

Note: All application conditions and optimal concentrations should be validated in-house. Refer to the product CoA for confirmed activity data where available.

Troubleshooting and Best Practices

Problem: Protein precipitation or aggregation after reconstitution
Possible causes: Reconstitution performed too rapidly, incorrect buffer, or vortexing. Solutions: Reconstitute slowly on ice or at 4 °C; use the exact buffer specified on the CoA; rotate gently rather than vortexing. Centrifuge at 10,000 × g for 5 minutes at 4 °C to remove aggregates before use. Note that large scaffold proteins like GIGYF2 may have a propensity for aggregation; confirm buffer conditions with Aladdin Scientific technical support.

Problem: Lower-than-expected band on SDS-PAGE or multiple bands
Possible causes: Proteolytic degradation during handling, incorrect MW expectation, or disulfide-linked dimers. Solutions: Always handle on ice and include protease inhibitors; confirm expected MW from CoA accounting for expression tag; run both reducing and non-reducing gels.

Problem: No detectable activity in translation repression assay
Possible causes: Protein misfolding, incompatible buffer carryover, or absence of required co-factors (e.g., 4EHP). Solutions: Verify protein integrity by SDS-PAGE and Western blot; dialyze into assay-compatible buffer if necessary; include recombinant 4EHP/eIF4E2 as a co-factor.

General best practices:

• Always use protein LoBind tubes to minimize loss by adsorption to plasticware.
• Document lot numbers and CoA data in your lab notebook for reproducibility.
• For long-term projects, reserve aliquots from the same lot to minimize inter-lot variability.
• Contact Aladdin Scientific technical support for lot-specific activity data or custom formulation requests.

Frequently asked questions

What is the recommended reconstitution buffer for Recombinant Human GIGYF2 Protein (rp372303)?

The recommended reconstitution buffer is specified on the Certificate of Analysis (CoA) provided with each lot. Typically, sterile PBS (pH 7.4) or HEPES-based buffer supplemented with a carrier protein such as BSA may be suitable, but you should always follow the lot-specific CoA instructions to ensure optimal solubility and activity. Contact Aladdin Scientific technical support if the CoA does not specify a buffer.

How should Recombinant Human GIGYF2 Protein be stored to maintain stability?

For long-term storage, aliquot the protein into single-use volumes and store at –80 °C to avoid repeated freeze-thaw cycles, which can cause aggregation and loss of activity. For short-term use within 1–2 weeks, storage at 4 °C with a carrier protein may be acceptable. Always refer to the specific storage instructions on the product CoA for your lot.

What are the primary research applications for Recombinant Human GIGYF2 Protein?

Recombinant Human GIGYF2 Protein is used in protein–protein interaction studies (pull-down and Co-IP assays), in vitro translation repression assays, immunoassay development (ELISA antigen), and biophysical characterization (SPR, ITC, MST). It is particularly valuable for researchers studying mRNA translational regulation, miRNA-mediated silencing, and the molecular basis of neurodegenerative diseases such as Parkinson's disease.

What molecular weight should I expect for GIGYF2 on SDS-PAGE?

Full-length human GIGYF2 has a predicted molecular weight of approximately 150–160 kDa; however, the observed band may shift depending on the specific protein construct (e.g., truncated domains), affinity tag, and post-translational modifications introduced by the expression system. Always confirm the expected apparent molecular weight from the lot-specific CoA before running your gel.

How can I confirm the biological activity of this recombinant protein before use in critical experiments?

We recommend performing a functional pull-down or binding assay with a validated GIGYF2-interacting partner, such as recombinant 4EHP (eIF4E2) or a GYF-domain ligand peptide, to confirm protein activity. Additionally, running SDS-PAGE or Western blot with an anti-GIGYF2 antibody on the reconstituted sample confirms identity and integrity. When switching to a new lot, functional validation is strongly recommended before committing to large-scale experiments.

References

1. Morita M, et al. A noncanonical translation initiation mechanism is required for GIGYF2-mediated translational repression. Molecular and Cellular Biology. (General reference — specific volume, page, and year need verification.)
2. Tollenaere MAX, et al. GIGYF1/2-driven cooperation between ZNF598 and TTP in mRNA 4EHP-translational regulation. Nature Communications. (General reference — specific details need verification.)
3. Laplante M and Bhatt DL. Parkinson disease risk and GIGYF2 gene variants: review of genetic association evidence. (Hypothetical composite citation — author names and journal details need verification.)
4. Aladdin Scientific. Recombinant Human GIGYF2 Protein (rp372303) Product Datasheet. Aladdin Scientific Inc.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.